|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Zeng H and Zhang S: The
incidence and mortality of major cancers in China, 2012. Chin J
Cancer. 35(73)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W,
Guo RP and Shi M: Hepatic artery infusion chemotherapy using
mFOLFOX versus transarterial chemoembolization for massive
unresectable hepatocellular carcinoma: A prospective non-randomized
study. Chin J Cancer. 36(83)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multicenter, open-label study of oxaliplatin plus
fluorouracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shao YY, Huang CC, Liang PC and Lin ZZ:
Hepatic arterial infusion of chemotherapy for advanced
hepatocellular carcinoma. Asia Pac J Clin Oncol. 6:80–88.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li QJ, He MK, Chen HW, Fang WQ, Zhou YM,
Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial
infusion of oxaliplatin, fluorouracil, and leucovorin versus
transarterial chemoembolization for large hepatocellular carcinoma:
A Randomized phase III trial. J Clin Oncol. 40:150–160.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
He MK, Liang RB, Zhao Y, Xu YJ, Chen HW,
Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al: Lenvatinib,
toripalimab, plus hepatic arterial infusion chemotherapy versus
lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv
Med Oncol. 13(17588359211002720)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mai Q, Mo Z, Shi F and Chen X: Lenvatinib
plus hepatic arterial infusion of modified FOLFOX regime in
patients with advanced hepatocellular carcinoma. J Clin Oncol. 38
(Suppl 15):2020.
|
|
9
|
Gu YK, Zhang TQ, Huang ZL, Geng ZJ, Chen
C, LI FG, Xu L, Sun J, LI J, Huang ZM and Shen L: Hepatic artery
infusion chemotherapy combined with apatinib and toripalimab in
advanced hepatocellular carcinoma: Real-world data from a single
center. J Clin Oncol. 38 (Suppl 15)(e16602)2020.
|
|
10
|
Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng
Z, Gu S, Wang L and Zou J: A phase II study of anti-PD1 antibody
camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as
first-line therapy for advanced hepatocellular carcinoma or biliary
tract cancer. J Clini Oncol. 37 (Suppl 15)(4074)2019.
|
|
11
|
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu
SX, Zhang X, Wang XD, Cao G, Chen H, et al: Real-world study of
hepatic artery infusion chemotherapy combined with anti-PD-1
immunotherapy and tyrosine kinase inhibitors for advanced
hepatocellular carcinoma. Immunotherapy. 13:1395–1405.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gupta A, De Felice KM, Loftus EV Jr and
Khanna S: Systematic review: Colitis associated with anti-CTLA-4
therapy. Aliment Pharmacol Ther. 42:406–417. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dougan M: Gastrointestinal and hepatic
complications of immunotherapy: Current management and future
perspectives. Curr Gastroenterol Rep. 22(15)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sugiyama Y, Tanabe H, Matsuya T, Kobayashi
Y, Murakami Y, Sasaki T, Kunogi T, Takahashi K, Ando K, Ueno N, et
al: Severe immune checkpoint inhibitor-associated gastritis: A case
series and literature review. Endosc Int Open. 10:E982–E989.
2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Anteby R, Kemeny NE, Kingham TP,
D'Angelica MI, Wei AC, Balachandran VP, Drebin JA, Brennan MF,
Blumgart LH and Jarnagin WR: Getting chemotherapy directly to the
liver: The historical evolution of hepatic artery chemotherapy. J
Am Coll Surg. 232:332–338. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Doria MI Jr, Doria LK, Faintuch J and
Levin B: Gastric mucosal injury after hepatic arterial infusion
chemotherapy with floxuridine. A clinical and pathologic study.
Cancer. 73:2042–2047. 1994.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Suzuki H and Ishii H: Peptic ulcer disease
complicated with liver cirrhosis. Nihon Rinsho. 62:532–540.
2004.PubMed/NCBI(In Japanese).
|
|
18
|
Hu J, Cao G, Xu L, Zheng K, Zhu X, Yang R
and Wang X and Wang X: Retrograde embolization technique of the
right gastric artery during the implantation of port-catheter
system for hepatic arterial infusion chemotherapy. J Interv Med.
4:27–31. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yamagami T, Arai Y, Matsueda K, Inaba Y,
Sueyoshi S and Takeuchi Y: The cause of nontumorous defects of
portal perfusion in the hepatic hilum revealed by CT during
arterial portography. AJR Am J Roentgenol. 172:397–402.
1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Imamine R, Shibata T, Shinozuka K and
Togashi K: Complications in hepatic arterial infusion chemotherapy:
Retrospective comparison of catheter tip placement in the
right/left hepatic artery vs. the gastroduodenal artery. Surg
Today. 47:851–858. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gonzalez RS, Salaria SN, Bohannon CD,
Huber AR, Feely MM and Shi C: PD-1 inhibitor gastroenterocolitis:
Case series and appraisal of ‘immunomodulatory
gastroenterocolitis’. Histopathology. 70:558–567. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ai Q, Chen W, Li Y and Li G: Upper
Gastrointestinal Tract IrAEs: A case report about
sintilimab-induced acute erosive hemorrhagic gastritis. Front
Immunol. 13(840916)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kobayashi M, Yamaguchi O, Nagata K, Nonaka
K and Ryozawa S: Acute hemorrhagic gastritis after nivolumab
treatment. Gastrointest Endosc. 86:915–916. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Onuki T, Morita E, Sakamoto N, Nagai Y,
Sata M and Hagiwara K: Severe upper gastrointestinal disorders in
pembrolizumab-treated non-small cell lung cancer patient. Respirol
Case Rep. 6(e00334)2018.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Zhang ML, Neyaz A, Patil D, Chen J, Dougan
M and Deshpande V: Immune-related adverse events in the
gastrointestinal tract: Diagnostic utility of upper
gastrointestinal biopsies. Histopathology. 76:233–243.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Patil PA and Zhang X: Pathologic
manifestations of gastrointestinal and hepatobiliary injury in
immune checkpoint inhibitor therapy. Arch Pathol Lab Med.
145:571–582. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen JH, Pezhouh MK, Lauwers GY and Masia
R: Histopathologic features of colitis due to immunotherapy with
anti-PD-1 antibodies. Am J Surg Pathol. 41:643–654. 2017.PubMed/NCBI View Article : Google Scholar
|
